Rita de Cássia Melo Vilhena de Andrade Fonseca da Silva
Federal University of Paraná
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Hotspot
Dive into the research topics where Rita de Cássia Melo Vilhena de Andrade Fonseca da Silva is active.
Publication
Featured researches published by Rita de Cássia Melo Vilhena de Andrade Fonseca da Silva.
Canadian Journal of Physiology and Pharmacology | 2016
Angélica K. Bernardelli; Rita de Cássia Melo Vilhena de Andrade Fonseca da Silva; Thiago Corrêa; José Eduardo da Silva-Santos
We evaluated the effects of phenylephrine, norepinephrine, angiotensin II, and vasopressin in mesenteric, renal, carotid, and tail arteries, and in perfused mesenteric vascular bed from rats subjected to the cecal ligation and puncture (CLP) model of sepsis. Phenylephrine and angiotensin II were less efficacious in mesenteric arteries from the CLP 6 h and CLP 18 h groups than in preparations from non-septic animals, but no differences were found for norepinephrine and vasopressin between the preparations. In renal arteries, none of the vasoconstrictors had impaired activity in the CLP groups. Nonetheless, carotid arteries from the CLP 18 h group presented reduced reactivity to all vasoconstrictors tested, but only phenylephrine and norepinephrine had their effects reduced in carotid arteries from the CLP 6 h group. Despite the reduced responsiveness to phenylephrine, tail arteries from septic rats were hyperreactive to vasopressin and norepinephrine at 6 h and 18 h after the CLP surgery, respectively. The mesenteric vascular bed from CLP groups was hyporeactive to phenylephrine, norepinephrine, and angiotensin II, but not to vasopressin. The vascular contractility in sepsis varies from the well-described refractoriness, to unaltered or even hyperresponsiveness to vasoconstrictors, depending on the vessel, the vasoactive agent, and the time period evaluated.
Biomedicine & Pharmacotherapy | 2018
Luísa Nathália Bolda Mariano; Thaise Boeing; Rita de Cássia Melo Vilhena de Andrade Fonseca da Silva; Valdir Cechinel-Filho; Rivaldo Niero; Luisa Mota da Silva; Priscila de Souza; Sérgio Faloni de Andrade
Several studies have suggested that (-)-epicatechin-containing foods and plant extracts benefit conditions that affect the cardiovascular system, such as hypertension and endothelial dysfunction. However, no study was conducted so far to evaluate the potential of this flavonoid on diuretic activity assay. For that, female Wistar normotensive (NTR) and spontaneously hypertensive rats (SHR) received a single oral treatment with (-)-epicatechin (EPI), hydrochlorothiazide (HCTZ) or just vehicle (VEH). The effects of EPI in combination with diuretics for clinical use, as well as with L-NAME, atropine and indomethacin were also explored. Cumulative urine volume, plasma and urinary parameters were evaluated at the end of 8 h experiment. When given to NTR and SHR, at doses of 0.3, 1 and 3 mg/kg, EPI was able to stimulate both diuresis and saluresis (Na+, K+ and Cl-), without interfering with plasma electrolyte content or urinary pH and uric acid values, when compared with VEH-treated only rats. The combination with HCTZ, but not with furosemide or amiloride, successfully strengthened EPI-induced diuresis. This effect was not accompanied by a potentiation of the saluretic effects. On the other hand, when given EPI in combination with amiloride, a significant increase in Cl- excretion and maintenance of the potassium-sparing effects characteristic of this class of diuretics were detected. In addition, the diuretic effect of EPI was enhanced after pretreatment with L-NAME and its action was significantly precluded in the presence of indomethacin, a cyclooxygenase inhibitor. In conclusion, this study shows the diuretic and saluretic properties of EPI in rats, adding another biological activity whose effect may contribute to the different positive actions already described.
Journal of Ethnopharmacology | 2012
Rita de Cássia Melo Vilhena de Andrade Fonseca da Silva; Sandra Crestani; Priscila de Souza; Aline Augusti Boligon; Margareth Linde Athayde; Adair R.S. Santos; Maria Consuelo Andrade Marques; Cândida Aparecida Leite Kassuya; José Eduardo da Silva-Santos
Journal of Ethnopharmacology | 2013
Priscila de Souza; Sandra Crestani; Rita de Cássia Melo Vilhena de Andrade Fonseca da Silva; Francielli Gasparotto; Cândida Aparecida Leite Kassuya; José Eduardo da Silva-Santos; Arquimedes Gasparotto Junior
Journal of Ethnopharmacology | 2015
Rita de Cássia Melo Vilhena de Andrade Fonseca da Silva; Priscila de Souza; Sandra Crestani; Arquimedes Gasparotto Junior; Aline Augusti Boligon; Margareth Linde Athayde; José Eduardo da Silva-Santos
Digestive Diseases and Sciences | 2017
Luisa Mota da Silva; Rita de Cássia Melo Vilhena de Andrade Fonseca da Silva; Daniele Maria-Ferreira; Olair Carlos Beltrame; José Eduardo da Silva-Santos; Maria Fernanda de Paula Werner
Applied Physiology, Nutrition, and Metabolism | 2016
Rita de Cássia Melo Vilhena de Andrade Fonseca da Silva; Priscila de Souza; José Eduardo da Silva-Santos
Naunyn-schmiedebergs Archives of Pharmacology | 2018
Fabile Schlickmann; Thaise Boeing; Luísa Nathália Bolda Mariano; Rita de Cássia Melo Vilhena de Andrade Fonseca da Silva; Luisa Mota da Silva; Sérgio Faloni de Andrade; Priscila de Souza; Valdir Cechinel-Filho
Journal of Ethnopharmacology | 2018
Philipe Costa; Marília O. Almeida; Marivane Lemos; Caroline Arruda; Rosana Casoti; Lincon Bordignon Somensi; Thaise Boeing; Marihá Mariott; Rita de Cássia Melo Vilhena de Andrade Fonseca da Silva; Bruna De Paoli Stein; Priscila de Souza; Ana Caroline dos Santos; Jairo Kenupp Bastos; Luisa Mota da Silva; Sérgio Faloni de Andrade
Inflammopharmacology | 2018
Luisa Mota da Silva; Lígia Moura Burci; Sandra Crestani; Priscila de Souza; Rita de Cássia Melo Vilhena de Andrade Fonseca da Silva; Nessana Dartora; Lauro Mera de Souza; Thales R. Cipriani; José Eduardo da Silva-Santos; Eunice André; Maria Fernanda de Paula Werner